Abstract No.
PD9-02
2020 San Antonio Breast Cancer Symposium
,
Dec 8-11
,
2020
Personalized circulating tumor DNA (ctDNA) as predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without pembrolizumab (P)
Magbanua MJM, Wolf D, Renner D, Shchegrova S, Brown Swigart L, Yau C, Hirst G, Wu H-T, Kalashnikova E, Tin A, Delson A, Yee D, DeMichele A, Salari R, Rodriguez A, Zimmermann B, Sethi H, Aleshin A, Billings P, Esserman L, Liu M, Nanda R, van ‘t Veer L, I-SPY 2 Investigators
coming soon
View original
